Indivior PLC (NASDAQ:INDV) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Indivior PLC (NASDAQ:INDV) have been assigned an average rating of “Buy” from the seven brokerages that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $39.3333.

INDV has been the subject of several research reports. Zacks Research upgraded Indivior from a “hold” rating to a “strong-buy” rating in a report on Monday, March 16th. Weiss Ratings lowered shares of Indivior from a “hold (c+)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th.

Insider Activity at Indivior

In other Indivior news, CFO Ryan Preblick sold 36,000 shares of the business’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $37.70, for a total value of $1,357,200.00. Following the completion of the sale, the chief financial officer owned 284,751 shares of the company’s stock, valued at $10,735,112.70. The trade was a 11.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.74% of the stock is currently owned by company insiders.

Institutional Trading of Indivior

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Salomon & Ludwin LLC acquired a new stake in Indivior in the 4th quarter worth approximately $30,000. Harbor Capital Advisors Inc. lifted its holdings in Indivior by 309.9% in the 4th quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company’s stock worth $37,000 after purchasing an additional 781 shares during the last quarter. Quarry LP acquired a new stake in Indivior in the 3rd quarter worth approximately $26,000. Caitong International Asset Management Co. Ltd lifted its holdings in Indivior by 72.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company’s stock worth $39,000 after purchasing an additional 460 shares during the last quarter. Finally, GAMMA Investing LLC lifted its holdings in Indivior by 544.6% in the 4th quarter. GAMMA Investing LLC now owns 1,199 shares of the company’s stock worth $43,000 after purchasing an additional 1,013 shares during the last quarter. Institutional investors and hedge funds own 60.33% of the company’s stock.

Indivior Price Performance

Shares of NASDAQ INDV opened at $38.01 on Friday. The company has a market capitalization of $4.63 billion, a P/E ratio of 19.49 and a beta of 0.88. Indivior has a one year low of $13.45 and a one year high of $41.00. The business’s 50-day moving average price is $35.75 and its two-hundred day moving average price is $34.38.

Indivior (NASDAQ:INDV) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $0.96 earnings per share (EPS) for the quarter. The business had revenue of $317.00 million during the quarter. Indivior had a negative return on equity of 219.26% and a net margin of 19.44%. On average, equities analysts anticipate that Indivior will post 4.05 EPS for the current year.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.